Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
01:11pm, Monday, 28'th Apr 2025
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
09:15am, Friday, 25'th Apr 2025
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline
11:09am, Thursday, 24'th Apr 2025
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Biogen Keep the Beat Streak Alive This Earnings Season?
07:55am, Thursday, 24'th Apr 2025
In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
12:50pm, Wednesday, 16'th Apr 2025
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
11:47am, Tuesday, 15'th Apr 2025
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.
Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?
10:55am, Thursday, 10'th Apr 2025
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag
05:34am, Wednesday, 09'th Apr 2025
Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
11:50am, Thursday, 03'rd Apr 2025
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate.
Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
07:30am, Wednesday, 02'nd Apr 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an inves
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
07:30am, Monday, 24'th Mar 2025
CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a mul
Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
02:39pm, Tuesday, 18'th Mar 2025
Biogen Inc. (NASDAQ:BIIB ) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Paul Matteis - Stif
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
12:36pm, Friday, 14'th Mar 2025
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
10:40am, Friday, 14'th Mar 2025
Sales of Biogen's BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is re
